Thyrocare Technologies Ltd
Q1 FY27, unaudited
- Revenue
- ₹225.66 Cr
- Profit after tax
- ₹50.17 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 225.66 | +26.14% | 774.27 |
| Other income | 3.51 | −11.36% | 13.39 |
| Total income | 229.17 | +25.33% | 787.66 |
| Employee benefit expense | 37.16 | +21.04% | 128.29 |
| Finance costs | 1.26 | +103.23% | 2.18 |
| Depreciation & amortisation | 11.23 | +25.47% | 51.17 |
| Total expenses | 162.54 | +23.19% | 571.29 |
| Profit before tax | 66.63 | +30.88% | 210.40 |
| Tax expense | 16.46 | +10.77% | 61.59 |
| Profit after tax | 50.17 | +39.17% | 148.81 |
| Total comprehensive income | 50.65 | +41.32% | 149.03 |
| Earnings per share, basic | ₹3.15 | ₹9.36 |
|---|---|---|
| Earnings per share, diluted | ₹3.14 | ₹9.34 |
Earnings call
Q1 FY27Thyrocare reported consolidated revenue growth of 24.3% and standalone revenue growth of 26.1% in Q1 FY27, with pathology business revenue growing 26% year-on-year. Management highlighted the commercial launch of its Specialty Diagnostics business covering allergy and genomics testing, alongside continued growth in franchisee and partnership channels. The company also discussed a planned divestment of its radiology/nuclear business and updates on franchisee network expansion.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 64 published by the exchange
19 Aug 2026
19 Aug 2026
18 Aug 2026
Insider tradingDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Appears 3 times in the recent filings shown; listed once.
18 Aug 2026
18 Aug 2026
17 Aug 2026
17 Aug 2026
14 Aug 2026
Insider tradingDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Appears 2 times in the recent filings shown; listed once.
13 Aug 2026
Insider tradingDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Appears 2 times in the recent filings shown; listed once.
13 Aug 2026
13 Aug 2026
27 Jul 2026
Transcript
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 19 Aug 2026.